1. Home
  2. JANX vs OPEN Comparison

JANX vs OPEN Comparison

Compare JANX & OPEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JANX
  • OPEN
  • Stock Information
  • Founded
  • JANX 2017
  • OPEN 2014
  • Country
  • JANX United States
  • OPEN United States
  • Employees
  • JANX N/A
  • OPEN N/A
  • Industry
  • JANX Biotechnology: Pharmaceutical Preparations
  • OPEN Real Estate
  • Sector
  • JANX Health Care
  • OPEN Finance
  • Exchange
  • JANX Nasdaq
  • OPEN Nasdaq
  • Market Cap
  • JANX 1.4B
  • OPEN 1.4B
  • IPO Year
  • JANX 2021
  • OPEN N/A
  • Fundamental
  • Price
  • JANX $24.87
  • OPEN $3.30
  • Analyst Decision
  • JANX Strong Buy
  • OPEN Sell
  • Analyst Count
  • JANX 8
  • OPEN 4
  • Target Price
  • JANX $90.63
  • OPEN $1.45
  • AVG Volume (30 Days)
  • JANX 892.8K
  • OPEN 370.6M
  • Earning Date
  • JANX 08-07-2025
  • OPEN 08-05-2025
  • Dividend Yield
  • JANX N/A
  • OPEN N/A
  • EPS Growth
  • JANX N/A
  • OPEN N/A
  • EPS
  • JANX N/A
  • OPEN N/A
  • Revenue
  • JANX $439,000.00
  • OPEN $5,181,000,000.00
  • Revenue This Year
  • JANX N/A
  • OPEN N/A
  • Revenue Next Year
  • JANX $1,470.83
  • OPEN $18.95
  • P/E Ratio
  • JANX N/A
  • OPEN N/A
  • Revenue Growth
  • JANX N/A
  • OPEN 14.07
  • 52 Week Low
  • JANX $21.97
  • OPEN $0.51
  • 52 Week High
  • JANX $71.71
  • OPEN $4.97
  • Technical
  • Relative Strength Index (RSI)
  • JANX 51.13
  • OPEN 69.37
  • Support Level
  • JANX $23.96
  • OPEN $2.26
  • Resistance Level
  • JANX $25.93
  • OPEN $2.67
  • Average True Range (ATR)
  • JANX 1.55
  • OPEN 0.36
  • MACD
  • JANX 0.06
  • OPEN 0.05
  • Stochastic Oscillator
  • JANX 61.91
  • OPEN 90.88

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About OPEN Opendoor Technologies Inc

Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.

Share on Social Networks: